TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04993664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second group will receive placebo. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
Study: NCT04857983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
Study: NCT04227314
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period,
Study: NCT05746897
Drug: NM1F Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period.
Study: NCT05539729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo created by the IDS and encapsulated in red coating to match the Study Drug.
Study: NCT06259721
Drug: Anti-PD1 antibody, nimotuzumab and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment.
Study: NCT06290349
Drug: DA5221-T1
Normalized name: FORTISCARE T1 (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA5221-T1 + DA5221-R2, orally, once daily, up to 24 weeks
Study: NCT06290349
Drug: DA5221-T2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA5221-R1 + DA5221-T2, orally, once daily, up to 24 weeks
Study: NCT06290349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA5221-R1 + DA5221-R2, orally, once daily, up to 24 weeks
Study: NCT06290349
Drug: DA5221-B1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA5221-B1, orally, daily for background therapy
Study: NCT05465434
Drug: Zinc Supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc sulphate 50 mg
Study: NCT04811404
Drug: Ethyl Eicosapentaenoic Acid
Normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment will be for six weeks
Study: NCT00000966
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000966
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06440694
Drug: Placebo 0.5 mg po
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.5 mg po once daily for 180 days.
Study: NCT05000463
Drug: Convtrol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.
Study: NCT05465460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet orally four times per day for 14 days
Study: NCT06470880
Drug: Adaptive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: A blood test that measures the amount of tumour DNA circulating in the patient's blood (known as ctDNA) will be conducted every two weeks to check if the cancer cells are still present, and if they are becoming active. The result of this test will allow doctors to monitor the activity of the tumour and judge when to pause and resume encorafenib and binimetinib treatment. This intermittent treatment is called 'adaptive therapy'.
Study: NCT06470880
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib and binimetinib delivered to UK standard of care.
Study: NCT04812067
Drug: TTHX1114
Approvals — FDA: no, EMA: no, PMDA: no
Description: engineered FGF-1
Study: NCT06254742
Drug: HHPG-19K Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: first cycle: Auto-HHPG-19K Injection or HHPG-19K Injection second cycle: HHPG-19K Injection or Auto-HHPG-19K Injection
Study: NCT05564819
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.
Study: NCT05429788
Drug: placebo inhaled dry powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhaled powder administered before public speaking challenge
Study: NCT05405387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
Study: NCT05585866
Drug: Anesthesia Agent
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
Study: NCT04092647
Drug: Ashwagandha
Normalized name: Ashwagandha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha 350 mg po BID
Study: NCT04092647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 350 mg po BID
Study: NCT06003608
Drug: Levodopa-Carbidopa Immediate Release
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, Levodopa-Carbidopa Immediate Release
Study: NCT06230523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05280028
Drug: Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
Study: NCT06061146
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 immunotherapy
Study: NCT06061146
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT06061146
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT06414408
Drug: Doxycycline Pill
Normalized name: doxycycline Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg Dose
Study: NCT05524571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT04589650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo once daily up to week 16.
Study: NCT06143878
Drug: JNJ-77242113 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 matching placebo will be administered orally.
Study: NCT04937101
Drug: Chlorpheniramine-Codeine
Normalized name: chlorpheniramine-codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
Study: NCT05226923
Drug: KSP-1007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple doses, intravenous administration
Study: NCT06012097
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: using diclofenac as a comparator
Study: NCT05906628
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT06658353
Drug: VC004 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC004 Capsules BID
Study: NCT05361408
Drug: Zoledronic acid, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 5mg zoledronic acid, once
Study: NCT05227937
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
Study: NCT05889273
Drug: ML-004 (IR)/(ER) tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ML-004 once daily.
Study: NCT06297967
Drug: Acetic Acid
Normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention treatment will consist of cleaning with water and soap, application of a compress soaked in 2% dilution of glacial acetic acid (CAS 64-19-7) for 15 minutes, irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the ulcer bed. Depending on the amount of exudate, more or less alginate will be added as a secondary dressing. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
Study: NCT06297967
Drug: Prontosan
Normalized name: PRONTOSAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment includes ulcer cleansing with water and soap, application of ProntosanⓇ compress for 15 minutes, subsequent irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the wound bed. More or less alginate will be applied depending on the amount of exudate. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
Study: NCT04787848
Drug: Relistor Injectable Product
Normalized name: Relistor Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
Study: NCT04278963
Drug: YinHu QingWen Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
Study: NCT04991909
Drug: HRS4800
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS4800
Study: NCT04991909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05590468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Looks exactly like the study drug, but it contains no active ingredient
Study: NCT04311632
Drug: Corticosteroids (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Concomitant Immunosuppression
Study: NCT05795699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution
Study: NCT05387525
Drug: Diclofenac Sodium 3% Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
Study: NCT04079088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04079088
Drug: BIIB061
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05306353
Drug: Placebo for VIB4920
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)
Study: NCT05306353
Drug: VIB4920 with TNFi
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)
Study: NCT05306353
Drug: VIB4920 without TNFi
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
Study: NCT06194188
Drug: Subcutaneous injection of CU-20401
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.
Study: NCT05424380
Drug: GSK3745417
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3745417 will be administered
Study: NCT06207981
Drug: induction chemotherapy (mDCF)
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days)
Study: NCT06491940
Drug: Losartan + Hydrochlorothiazide
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
Study: NCT05660863
Drug: MN-08 24 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
Study: NCT05660863
Drug: MN-08 60 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
Study: NCT05360446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
Study: NCT05958199
Drug: NPX267
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPX267 will be administered by intravenous infusion every three weeks until documented disease progression or participant withdrawal
Study: NCT05762107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receives Placebo by subcutaneous injection daily for 28 days
Study: NCT05762107
Drug: ZT-01, 7 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
Study: NCT05762107
Drug: ZT-01, 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
Study: NCT05762107
Drug: ZT-01, 22 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
Study: NCT05665062
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: lymphodepletion
Study: NCT06002230
Drug: Homeopathic medicines
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Globules were administered orally..
Study: NCT05774236
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
Study: NCT05415748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
Study: NCT04880187
Drug: AXA1125
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXA1125 administered BID with or without food
Study: NCT04880187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo administered BID with or without food
Study: NCT05656495
Drug: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly
Normalized name: D-alanyl-3-(2-naphthyl)-d-alanyl-l-alanyl-l-tryptophyl-d-phenylalanyl-l-lysinamide
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
Study: NCT05005494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of NaCl (sodium chloride) 0.9% (placebo eq. 0.5ml/kg of NaCl 0.9%)
Study: NCT05656495
Drug: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled
Normalized name: D-alanyl-3-(2-naphthyl)-d-alanyl-l-alanyl-l-tryptophyl-d-phenylalanyl-l-lysinamide
DrugBank: Pralmorelin (DB18252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
Study: NCT05656495
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
Study: NCT04624659
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT04951076
Drug: BNC210
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC210 900 mg twice daily (b.i.d.) for 12 weeks
Study: NCT04951076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily (b.i.d.) for 12 weeks
Study: NCT05182476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT06191744
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Injection
Study: NCT06191744
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Injection
Study: NCT05366842
Drug: Stravix lyopreserved placental tissue (LPT)
Normalized name: human placental tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo surgical implantation of Stravix lyopreserved placental tissue (LPT) during a standard of care radical prostatectomy.
Study: NCT05787873
Drug: SIPS-2209-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05787873
Drug: SIPS-2209-2, SIPS-2209-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05764057
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended.
Study: NCT00005921
Drug: L-743,872
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05535959
Drug: VX-121/TEZ/D-IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet for oral administration.
Study: NCT04710381
Drug: IMUNOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease
Study: NCT04843449
Drug: ASC40
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01151930
Drug: SCB01A
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
Study: NCT06605950
Drug: KarXT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06605950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05288881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo administered by IV infusion.
Study: NCT06264453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical applications of Water for Injection
Study: NCT04710030
Drug: Placebo sugar pill caplet
Normalized name: Feosol Caplet Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT04826393
Drug: ASP8374
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 3 weeks by intravenous infusion
Study: NCT04226690
Drug: matched placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
Study: NCT05242692
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refer to either S-ketamine or Dexmedetomidine